No Access
Sponsored by
The University of Chicago Booth School
of Business and The University of Chicago Law School
Article DOI
https://doi.org/10.1086/467136
Views: 16
Total views on this site
Total views on this site
Citations: 17
Citations are reported from Crossref
Citations are reported from Crossref
Copyright 1987 The University of Chicago
Crossref reports the following articles citing this article:
Peter T. Leeson, Henry A. Thompson Public choice and public health,Public Choice 195, no.1-21-2 (Mar 2021): 5–41.Joseph T. F. Roberts How to Regulate the Right to Self-Medicate,HEC Forum 34, no.33 (Jun 2020): 233–255.Matthew J. Higgins, Xin Yan, Chirantan Chatterjee Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling,Research Policy 50, no.11 (Jan 2021): 104126.Anqi Wu, Yixin (Iris) Wang The More Monitoring, the Better Quality? Empirical Evidence from the Generic Drug Industry,SSRN Electronic Journal 23 (Jan 2019).David Barker Ethics and Lobbying: The Case of Real Estate Brokerage,Journal of Business Ethics 80, no.11 (Jun 2007): 23–35.Mary K. Olson The risk we bear: The effects of review speed and industry user fees on new drug safety,Journal of Health Economics 27, no.22 (Mar 2008): 175–200.F.M. Scherer Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost,Managerial and Decision Economics 28, no.4-54-5 (Aug 2007): 267–283.Ahmed Khwaja, Frank Sloan, Martin Salm Evidence on preferences and subjective beliefs of risk takers: The case of smokers,International Journal of Industrial Organization 24, no.44 (Jul 2006): 667–682.Jean-Philippe Bonardi, Amy J Hillman, Gerald D. Keim The Attractiveness of Political Markets: Implications for Firm Strategy,Academy of Management Review 30, no.22 (Apr 2005): 397–413.Mary K. Olson Pharmaceutical Policy Change and the Safety of New Drugs Olson,The Journal of Law and Economics 45, no.S2S2 (Jul 2015): 615–642.Theodore E. Keeler, Teh‐wei Hu, Alison Keith, Richard Manning, Martin D. Marciniak, Michael Ong, Hai‐Yen Sung The benefits of switching smoking cessation drugs to over‐the‐counter status,Health Economics 11, no.55 (Jan 2002): 389–402.Anthony M. Marino Regulation of product safety design through product testing,Journal of Regulatory Economics 7, no.33 (May 1995): 255–276.W. Kip Viscusi Do Smokers Underestimate Risks?,Journal of Political Economy 98, no.66 (Oct 2015): 1253–1269.Wesley A. Magat , and W. Kip Viscusi Effectiveness of the EPA's Regulatory Enforcement: The Case of Industrial Effluent Standards,The Journal of Law and Economics 33, no.22 (Oct 2015): 331–360.
